



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref:ISLL:CH:2014:

Date: 22nd July, 2014

The President,
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No.C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

SUB: IND-SWIFT LABORATORIES LIMITED - UPDATES

Dear Sir,

Pursuant to Clause 36 of the Listing Agreement, we are pleased to enclose herewith the Company's fund raising plans for new drug launches.

You are requested to kindly take the same on record.

Thanking you
for IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA
GM-CORPORATE AFFAIRS &
COMPANY SECRETARY

Encl.: As above



Ind-Swift LABORATORIES Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Company eyeing at Fund Raising for New Drugs Launch

The Company contemplates raising funds to expand the existing manufacturing capacities including the setting up a new multi product manufacturing blocks, debottlenecking and long term working capital requirements. The Company at present is ready with the commercial launch of the following products developed by its In-house state of the art Research and Development centre :

Name of Product	Global Market Size
ATORVASTATIN	US\$ 12bn
FEXOFENADINE	US\$ 1.5bn
ROSUVASTATIN	US\$ 6 bn
TEMOZOLAMIDE	US\$ 900mn
IVABRADINE	US\$154mn

Company eyes the market size in the range of more than 10% to 20% of the generic market of these drugs in coming years upon commercial launch .

The funds raised will enable the company to have capacities to manufacture these products at commercial pace and rise to the next EBIDTA level .

The Company is also eyeing for a strategic investors for which it has accorded mandate to a leading MNC Ernst & Young (EY) to conduct the due diligence process for the prospective foreign investors who have shown interest in the company .

